Protagenic Days Sales Outstanding from 2010 to 2025

PTIXW Stock  USD 0  0.00  0.00%   
Protagenic Therapeutics Days Sales Outstanding yearly trend continues to be fairly stable with very little volatility. Days Sales Outstanding is likely to outpace its year average in 2025. During the period from 2010 to 2025, Protagenic Therapeutics Days Sales Outstanding regression line of quarterly data had mean square error of  220.11 and geometric mean of  53.96. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
56.95
Current Value
94.58
Quarterly Volatility
14.38979286
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 24.1 K, Interest Expense of 137.6 K or Selling General Administrative of 1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.42. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Protagenic Therapeutics' Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Very volatile
   Days Sales Outstanding   
       Timeline  

Protagenic Days Sales Outstanding Regression Statistics

Arithmetic Mean55.26
Geometric Mean53.96
Coefficient Of Variation26.04
Mean Deviation9.33
Median49.53
Standard Deviation14.39
Sample Variance207.07
Range45.0543
R-Value0.09
Mean Square Error220.11
R-Squared0.01
Significance0.74
Slope0.27
Total Sum of Squares3,106

Protagenic Days Sales Outstanding History

2025 94.58
2024 56.95
2011 49.53
2010 88.87

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Days Sales Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Sales Outstanding 56.95  94.58 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.